Dissecting the role of the ATF4 stress response in T cell-mediated inflammation

剖析 ATF4 应激反应在 T 细胞介导的炎症中的作用

基本信息

  • 批准号:
    9240576
  • 负责人:
  • 金额:
    $ 23.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-08 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant) Reactive oxygen species (ROS) play a major role in the pathogenesis of chronic inflammatory and autoimmune diseases. It is well established that ROS modulate T cell-mediated immune responses. However, little is known about underlying molecular mechanisms of how ROS regulate T cell immune responses and how T cells adapt to high levels of ROS. Our goal is to elucidate the transcriptional network regulating T cell adaption to oxidative stress. In preliminary studies, we found ROS were elevated to much greater levels in CD4+ T cells cultured in Th1 conditions when compared to those cultured in Th0 and Th17 conditions. In further gene profiling studies, we demonstrated that ROS induced the gene expression signature of activating transcription factor-4 (ATF4) in activated Th1 cells in vitro an MOG-specific T cell in vivo. ATF4 is a basic leucine-zipper (bZip) transcription factor, which regulates cellular redox state and amino acid metabolism. We demonstrated that experimental allergic encephalomyelitis (EAE) was exacerbated in ATF4 deficient mice compared with wild type (WT) mice. Consistent with clinical scores of EAE, the number of autoreactive Th1 cells was decreased whereas that of autoreactive Th17 cells was elevated in ATF4 deficient mice compared with WT mice. We further showed that in vitro ATF4 deficiency in T cells resulted in great reduction of IFN-γ production in Th1 cultures and modest reduction of IL-17 in Th17 cultures. In contrast, in vitro, ATF4 deficiency in antigen presenting cells (APC) resulted in no change in IFN-γ production in Th1 cultures but an increase in IL-17 in Th17 cultures. Based on these new findings, we hypothesize that ATF4 promotes Th1 and suppresses Th17 immune responses in pathological conditions involving the oxidative stress. To test this hypothesis, we propose the following specific aims: Specific Aim 1. Determine the T cell autonomous role of ATF4 in Th1/Th17 differentiation in vivo. Specific Aim 2. Determine the role of ATF4 within myeloid cells in T helper cell differentiation in vivo.
 说明(由申请人提供)活性氧(ROS)在慢性炎症和自身免疫性疾病的发病机制中起主要作用。已经确定ROS调节T细胞介导的免疫应答。然而,关于ROS如何调节T细胞免疫应答以及T细胞如何适应高水平ROS的潜在分子机制知之甚少。我们的目标是阐明调节T细胞适应的转录网络 氧化应激。在初步研究中,我们发现,与Th 0和Th 17条件下培养的CD 4 + T细胞相比,Th 1条件下培养的CD 4 + T细胞中ROS升高到更高的水平。在进一步的基因分析研究中,我们证明了ROS诱导体外活化的Th 1细胞和体内MOG特异性T细胞中转录激活因子4(ATF 4)的基因表达特征。ATF 4是一种碱性亮氨酸拉链(bZip)转录因子,调节细胞氧化还原状态和氨基酸代谢。我们证明了与野生型(WT)小鼠相比,ATF 4缺陷小鼠的实验性过敏性脑脊髓炎(EAE)加重。与EAE的临床评分一致,与WT小鼠相比,ATF 4缺陷小鼠中自身反应性Th 1细胞的数量减少,而自身反应性Th 17细胞的数量增加。我们进一步表明,体外T细胞中的ATF 4缺陷导致Th 1培养物中IFN-γ产生的大幅减少和Th 17培养物中IL-17的适度减少。相反,在体外,抗原呈递细胞(APC)中的ATF 4缺陷导致Th 1培养物中IFN-γ产生无变化,但Th 17培养物中IL-17增加。基于这些新的发现,我们假设ATF 4在涉及氧化应激的病理条件下促进Th 1和抑制Th 17免疫应答。为了验证这一假设,我们提出了以下具体目标:具体目标1。确定ATF 4在体内Th 1/Th 17分化中的T细胞自主作用。具体目标2。确定骨髓细胞内ATF 4在体内T辅助细胞分化中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Binfeng Lu其他文献

Binfeng Lu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Binfeng Lu', 18)}}的其他基金

Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
IL-33 驱动的免疫细胞组织支持免疫检查点阻断癌症治疗反应的研究
  • 批准号:
    10703824
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
IL-33 驱动的免疫细胞组织支持免疫检查点阻断癌症治疗反应的研究
  • 批准号:
    10625415
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
IL-33 驱动的免疫细胞组织支持免疫检查点阻断癌症治疗反应的研究
  • 批准号:
    10431979
  • 财政年份:
    2021
  • 资助金额:
    $ 23.25万
  • 项目类别:
Cellular and molecular mechanisms underlying IL-33-mediated anti-tumor immunity
IL-33介导的抗肿瘤免疫的细胞和分子机制
  • 批准号:
    8443458
  • 财政年份:
    2013
  • 资助金额:
    $ 23.25万
  • 项目类别:
Cellular and molecular mechanisms underlying IL-33-mediated anti-tumor immunity
IL-33介导的抗肿瘤免疫的细胞和分子机制
  • 批准号:
    8602513
  • 财政年份:
    2013
  • 资助金额:
    $ 23.25万
  • 项目类别:
Immune Regulation by Gadd45b and Gadd45g
Gadd45b 和 Gadd45g 的免疫调节
  • 批准号:
    7330322
  • 财政年份:
    2006
  • 资助金额:
    $ 23.25万
  • 项目类别:
Immune Regulation by Gadd45b and Gadd45g
Gadd45b 和 Gadd45g 的免疫调节
  • 批准号:
    7031286
  • 财政年份:
    2006
  • 资助金额:
    $ 23.25万
  • 项目类别:
Immune Regulation by Gadd45b and Gadd45g
Gadd45b 和 Gadd45g 的免疫调节
  • 批准号:
    7545810
  • 财政年份:
    2006
  • 资助金额:
    $ 23.25万
  • 项目类别:
Immune Regulation by Gadd45b and Gadd45g
Gadd45b 和 Gadd45g 的免疫调节
  • 批准号:
    7162073
  • 财政年份:
    2006
  • 资助金额:
    $ 23.25万
  • 项目类别:
Immune Regulation by Gadd45b and Gadd45g
Gadd45b 和 Gadd45g 的免疫调节
  • 批准号:
    7746479
  • 财政年份:
    2006
  • 资助金额:
    $ 23.25万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 23.25万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 23.25万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 23.25万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 23.25万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 23.25万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 23.25万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 23.25万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 23.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了